

Jorge S Reis-Filho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8602794/publications.pdf>

Version: 2024-02-01

169
papers

19,602
citations

13827

67
h-index

11899

134
g-index

172
all docs

172
docs citations

172
times ranked

25750
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic characterization of small cell carcinomas of the uterine cervix. <i>Molecular Oncology</i> , 2022, 16, 833-845.	2.1	14
2	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	3.0	31
3	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2022, 35, 193-201.	2.9	25
4	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	3.2	13
5	Stromal <i>MED12</i> exon 2 mutations in complex fibroadenomas of the breast. <i>Journal of Clinical Pathology</i> , 2022, 75, 133-136.	1.0	2
6	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	9.6	132
7	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	3.0	3
8	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
9	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	2.6	9
10	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	0.6	9
11	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100365.	1.5	1
12	Genomic landscape of endometrial carcinomas of no specific molecular profile. <i>Modern Pathology</i> , 2022, 35, 1269-1278.	2.9	33
13	Recurrent <i>WWTR1</i> <i>S89W</i> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. <i>Journal of Pathology</i> , 2022, 257, 635-649.	2.1	2
14	LINCO0355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 49.	2.3	4
15	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 51.	2.3	9
16	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	15.2	125
17	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. <i>Nature Cancer</i> , 2022, 3, 723-733.	5.7	82
18	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38

#	ARTICLE	IF	CITATIONS
19	Problematic breast tumors reassessed in light of novel molecular data. <i>Modern Pathology</i> , 2021, 34, 38-47.	2.9	25
20	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	2.1	21
21	<scp>Whole-exome</scp> sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 113-120.	1.3	4
22	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. <i>Modern Pathology</i> , 2021, 34, 1213-1225.	2.9	28
23	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. <i>Modern Pathology</i> , 2021, 34, 994-1007.	2.9	19
24	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	1.6	13
25	A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor). <i>American Journal of Surgical Pathology</i> , 2021, 45, 1061-1074.	2.1	19
26	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. <i>Nature Communications</i> , 2021, 12, 259.	5.8	27
27	Homologous recombination deficiency: how genomic signatures are generated. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 93-100.	1.5	13
28	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K± Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.4	20
29	Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. <i>Modern Pathology</i> , 2021, 34, 1570-1587.	2.9	57
30	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	5.8	54
31	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	2.3	16
32	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. <i>Npj Breast Cancer</i> , 2021, 7, 45.	2.3	7
33	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. <i>Histopathology</i> , 2021, 79, 176-186.	1.6	4
34	Independent real-world application of a clinical-grade automated prostate cancer detection system. <i>Journal of Pathology</i> , 2021, 254, 147-158.	2.1	57
35	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	0.6	16
36	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1274-1281.	2.1	6

#	ARTICLE	IF	CITATIONS
37	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. <i>Modern Pathology</i> , 2021, 34, 1850-1859.	2.9	3
38	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 96.	2.3	38
39	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	6
40	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. <i>Gynecologic Oncology</i> , 2021, 163, 14-21.	0.6	6
41	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.	2.3	7
42	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	1.5	8
43	Ki67 Assessment in Breast Cancer: Are We There Yet?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 797-798.	3.0	7
44	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	2.3	9
45	HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. <i>Nature Communications</i> , 2021, 12, 6667.	5.8	47
46	Diverse alterations associated with resistance to KRAS(G12C) inhibition. <i>Nature</i> , 2021, 599, 679-683.	13.7	183
47	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. <i>Modern Pathology</i> , 2021, , .	2.9	3
48	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. <i>Modern Pathology</i> , 2021, , .	2.9	5
49	Sclerosing epithelioid mesenchymal neoplasm of the pancreas—A proposed new entity. <i>Modern Pathology</i> , 2020, 33, 456-467.	2.9	10
50	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. <i>Modern Pathology</i> , 2020, 33, 65-73.	2.9	29
51	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	1.6	19
52	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. <i>Nature Communications</i> , 2020, 11, 44.	5.8	34
53	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	2.9	35
54	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1217-1223.	1.5	1

#	ARTICLE	IF	CITATIONS
55	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	2.3	27
56	Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. <i>Histopathology</i> , 2020, 77, 321-326.	1.6	7
57	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
58	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	7.7	67
59	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). <i>American Journal of Surgical Pathology</i> , 2020, 44, 545-552.	2.1	39
60	Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020, 52, 582-593.	9.4	136
61	Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene. <i>International Journal of Cancer</i> , 2020, 147, 2253-2264.	2.3	10
62	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
63	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020, 6, 20.	2.3	25
64	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. <i>Modern Pathology</i> , 2020, 33, 1606-1617.	2.9	38
65	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	2.9	23
66	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	9.4	140
67	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	5.7	96
68	Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3682-3693.	3.2	42
69	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	2.3	39
70	How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Current Breast Cancer Reports</i> , 2019, 11, 175-184.	0.5	0
71	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. <i>Histopathology</i> , 2019, 75, 931-937.	1.6	16
72	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019, 32, 1734-1743.	2.9	38

#	ARTICLE	IF	CITATIONS
73	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, 6.	2.3	21
74	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	7.7	27
75	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. <i>Histopathology</i> , 2019, 75, 213-224.	1.6	46
76	Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma. <i>Histopathology</i> , 2019, 75, 193-201.	1.6	10
77	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. <i>Histopathology</i> , 2019, 75, 139-145.	1.6	22
78	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. <i>Molecular Oncology</i> , 2019, 13, 1684-1692.	2.1	21
79	Massively parallel sequencing analysis of benign melanocytic naevi. <i>Histopathology</i> , 2019, 75, 29-38.	1.6	12
80	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, 16830.	1.6	29
81	Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	10
82	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
83	Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	19
84	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. <i>Modern Pathology</i> , 2019, 32, 205-215.	2.9	22
85	Lobular Carcinomas <i>In Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 674-686.	3.2	44
86	Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. <i>Histopathology</i> , 2019, 74, 638-650.	1.6	11
87	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. <i>Gynecologic Oncology</i> , 2019, 152, 11-19.	0.6	66
88	Recurrent <i>MED12</i> exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. <i>Journal of Clinical Pathology</i> , 2019, 72, 258-262.	1.0	22
89	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 737-741.	3.0	68
90	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1030-1034.	3.0	90

#	ARTICLE	IF	CITATIONS
91	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. <i>Cancer Research</i> , 2018, 78, 3112-3121.	0.4	57
92	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting <i>IDH2</i> and <i>PIK3CA</i> : a validation cohort. <i>Histopathology</i> , 2018, 73, 339-344.	1.6	44
93	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	1.6	25
94	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i> - <i>NFIB</i> fusion gene. <i>Journal of Pathology</i> , 2018, 244, 143-150.	2.1	74
95	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. <i>Cell Reports</i> , 2018, 25, 1446-1457.	2.9	76
96	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	7.7	307
97	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	7.7	633
98	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018, 9, 3533.	5.8	92
99	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	5.8	105
100	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. <i>Current Breast Cancer Reports</i> , 2017, 9, 34-44.	0.5	11
101	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	15.2	111
102	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 3859-3870.	3.2	129
103	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. <i>Histopathology</i> , 2017, 71, 480-487.	1.6	2
104	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study. <i>Histopathology</i> , 2017, 71, 626-634.	1.6	26
105	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	3.2	91
106	Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. <i>Journal of Pathology</i> , 2017, 242, 165-177.	2.1	43
107	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. <i>Nature Communications</i> , 2017, 8, 857.	5.8	182
108	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. <i>Npj Breast Cancer</i> , 2017, 3, 40.	2.3	52

#	ARTICLE	IF	CITATIONS
109	Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 76-89.	0.9	26
110	The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.	1.9	118
111	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. <i>Nature Medicine</i> , 2017, 23, 929-937.	15.2	146
112	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , 2017, 3, 48.	2.3	63
113	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017, 30, 69-84.	2.9	48
114	Lack of <i>PRKD2</i> and <i>PRKD3</i> kinase domain somatic mutations in <i>PRKD1</i> wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland. <i>Histopathology</i> , 2016, 68, 1055-1062.	1.6	23
115	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016, 68, 1030-1039.	1.6	31
116	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i>TERT</i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016, 238, 508-518.	2.1	102
117	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring <i>TP53</i> somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.	2.1	52
118	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	1.6	22
119	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
120	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
121	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. <i>Npj Breast Cancer</i> , 2016, 2, 16035.	2.3	28
122	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.4	99
123	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	2.9	95
124	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	3.2	153
125	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	2.9	68
126	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	1.6	329

#	ARTICLE	IF	CITATIONS
127	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, 16036.	2.3	127
128	Uterine adenosarcomas are mesenchymal neoplasms. <i>Journal of Pathology</i> , 2016, 238, 381-388.	2.1	94
129	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	3.2	119
130	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.	2.1	53
131	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.	1.6	37
132	<i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast. <i>Histopathology</i> , 2015, 67, 719-729.	1.6	78
133	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv427.	3.0	164
134	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80
135	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , 2015, 237, 179-189.	2.1	133
136	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , 2015, 16, 107.	3.8	109
137	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. <i>Modern Pathology</i> , 2015, 28, 1603-1612.	2.9	100
138	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. <i>Modern Pathology</i> , 2015, 28, 340-351.	2.9	80
139	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. <i>Modern Pathology</i> , 2015, 28, 505-514.	2.9	180
140	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	1.1	77
141	PI3K Pathway Activation in High-Grade Ductal Carcinoma <i>In Situ</i> —Implications for Progression to Invasive Breast Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 2326-2337.	3.2	41
142	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. <i>Genome Biology</i> , 2014, 15, 484.	3.8	117
143	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. <i>Cell Reports</i> , 2014, 6, 514-527.	2.9	239
144	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , 2014, 232, 553-565.	2.1	88

#	ARTICLE	IF	CITATIONS
145	Metaplastic breast carcinoma: more than a special type. <i>Nature Reviews Cancer</i> , 2014, 14, 147-148.	12.8	69
146	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014, 46, 1166-1169.	9.4	188
147	Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions. <i>Gynecologic Oncology</i> , 2014, 134, 410-418.	0.6	79
148	Tackling the Diversity of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6380-6388.	3.2	141
149	Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. <i>Journal of Pathology</i> , 2012, 226, 84-96.	2.1	144
150	The landscape of cancer genes and mutational processes in breast cancer. <i>Nature</i> , 2012, 486, 400-404.	13.7	1,535
151	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. <i>Histopathology</i> , 2012, 60, E115-30.	1.6	52
152	Genetic Interactions in Cancer Progression and Treatment. <i>Cell</i> , 2011, 145, 30-38.	13.5	380
153	Gene expression profiling in breast cancer: classification, prognostication, and prediction. <i>Lancet, The</i> , 2011, 378, 1812-1823.	6.3	629
154	Germline mutations in RAD51D confer susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2011, 43, 879-882.	9.4	460
155	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. <i>Journal of Pathology</i> , 2010, 220, 562-573.	2.1	185
156	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. <i>Journal of Pathology</i> , 2010, 222, 282-298.	2.1	139
157	Breast cancer precursors revisited: molecular features and progression pathways. <i>Histopathology</i> , 2010, 57, 171-192.	1.6	286
158	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. <i>Modern Pathology</i> , 2010, 23, 951-960.	2.9	56
159	Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1938-1948.	13.9	3,233
160	Histological types of breast cancer: How special are they?. <i>Molecular Oncology</i> , 2010, 4, 192-208.	2.1	365
161	Breast cancer molecular profiling with single sample predictors: a retrospective analysis. <i>Lancet Oncology, The</i> , 2010, 11, 339-349.	5.1	318
162	Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. <i>Cancer Cell</i> , 2009, 15, 294-303.	7.7	521

#	ARTICLE	IF	CITATIONS
163	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 351-365.	1.5	80
164	Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 273-280.	1.1	208
165	Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. <i>Histopathology</i> , 2009, 55, 732-743.	1.6	48
166	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. <i>Modern Pathology</i> , 2009, 22, 1401-1414.	2.9	110
167	Histological and molecular types of breast cancer: is there a unifying taxonomy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 718-730.	12.5	353
168	Are triple-negative tumours and basal-like breast cancer synonymous?. <i>Breast Cancer Research</i> , 2007, 9, 404; author reply 405.	2.2	98
169	Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. <i>Clinical Cancer Research</i> , 2005, 11, 5175-5180.	3.2	577